ASND - Ascendis Pharma A/S

241.38
2.160   0.895%

Share volume: 782,379
Last Updated: 03-04-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.72%

PREVIOUS CLOSE
CHG
CHG%
$239.22
2.16
0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
5%
Profitability 0%
Dept financing 3%
Liquidity 50%
Performance 0%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-0.29%
1 Month
11.04%
3 Months
17.49%
6 Months
17.23%
1 Year
54.87%
2 Year
60.33%
Key data
Stock price
$241.38
P/E Ratio 
0.00
DAY RANGE
$234.00 - $242.65
EPS 
-$5.07
52 WEEK RANGE
$124.06 - $248.60
52 WEEK CHANGE
$59.32
MARKET CAP 
7.945 B
YIELD 
N/A
SHARES OUTSTANDING 
58.231 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
09-02-2025
BETA 
0.88
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$874,460
AVERAGE 30 VOLUME 
$848,497
Company detail
CEO: Jan M. Mikkelsen
Region: US
Website: ascendispharma.com
Employees: 640
IPO year: 2008
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

SKYTROFA for treating patients with growth hormone deficiency (GHD) Ascendis Pharma A/S focuses on developing therapeutics for unmet medical needs. It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD. TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia.

Recent news